pharmaphorum

FEBRUARY 9, 2021

million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours. The start of dosing in the phase 1/1b trial of the drug has been delayed by the COVID-19 pandemic, but recruitment of the target 80 participants with advanced solid tumours is reported to be ongoing.

Trials 57

Trials Gene Silencing RNA Gene Expression 57

pharmaphorum

JANUARY 6, 2021

Analysts are continuing to back Inventiva’s lanifibranor as a potential “best-in-class” drug for the fatty liver disease NASH, as the company prepares for the launch of a phase 3 trial in spring. The trial will take a while however, with results not due until the second half of 2023, with sales forecast to peak at around $2.6

Gene Silencing 52

Gene Silencing Regulation Pharma Companies Doctors 52

pharmaphorum

NOVEMBER 18, 2021

Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to acquire the biotech for $3.3 billion in cash. The transaction is expected to close in the fourth quarter of this year.

Gene Silencing 52

Gene Silencing RNA Protein Gene 52

pharmaphorum

JUNE 8, 2022

The UK medicines regulator has awarded Alnylam’s RNAi-based therapy zilebesiran for hypertension an ‘innovation passport ‘, a designation designed to speed up NHS access to promising new medicines. The study is enrolling adults whose blood pressure is not adequately controlled by standard medicines.

Gene Silencing 52

Gene Silencing Drugs Medicine Regulation 52

pharmaphorum

MARCH 4, 2021

But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan’s ageing Restasis potentially facing generic competition, there’s a lot to play for and two biotechs are aiming to disrupt the market. Azura’s dry eye drug on target in phase 2.

Gene Silencing 98

Gene Silencing FDA Approval Trials Marketing 98

Drug Discovery World

AUGUST 1, 2023

This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.

RNA 52

RNA Drugs Gene Silencing Vaccination 52